Payment overview · 2025
General Payments
$72,592.21
226 reported records · 27 companies
Healthcare provider profile · identity verified
Ajay D Deshpande, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TERRE HAUTE, IN · NPI 1629058680
Verified facts
What the public records show
CMS Open Payments records show Ajay D Deshpande, MD received $72,592.21 in general payments during 2025 across 226 reported records.
AstraZeneca Pharmaceuticals LP accounted for 96.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Bevespi Aerosphere, Eliquis, Glassia, Ofev, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ofev by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 1736 claims for Trelegy Ellipta by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYREM as an associated drug or biological on 613 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyrem by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69,886.21 | 96.3% | 81 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $755.99 | 1.0% | 38 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $317.86 | 0.4% | 11 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $197.63 | 0.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $190.69 | 0.3% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.43 | 0.2% | 9 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $137.68 | 0.2% | 18 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $91.40 | 0.1% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $88.75 | 0.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.56 | 0.1% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $74.39 | 0.1% | 4 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $71.89 | 0.1% | 4 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $65.65 | 0.1% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $60.59 | 0.1% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $51.18 | 0.1% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $49.52 | 0.1% | 5 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $48.43 | 0.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.00 | 0.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $40.92 | 0.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $35.39 | 0.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.03 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.07 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.82 | 0.0% | 1 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $21.24 | 0.0% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $15.78 | 0.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.38 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.73 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,450.00 | 23 |
| Food and Beverage | $5,010.51 | 183 |
| Travel and Lodging | $3,097.70 | 19 |
| Education | $34.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37,138.73 | 37 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32,469.34 | 26 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $334.40 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $287.30 | 17 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $284.62 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $281.76 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $258.22 | 9 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $248.55 | 8 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $143.81 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $137.68 | 18 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $134.29 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.62 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $105.62 | 5 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $91.40 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $88.75 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.56 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $87.56 | 5 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $74.39 | 4 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $71.89 | 4 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $65.65 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $51.18 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $49.52 | 5 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $48.43 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.81 | 4 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.03 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.03 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| BEVESPI AEROSPHERE bevespi aerosphere |
2025 | Bevespi Aerosphere | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 64 | exact normalized | Medicare Part D |
| GLASSIA glassia |
2025 | Glassia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 1736 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
146 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
1736 | 404 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYREM open payments reported associated product |
CMS Open Payments — General Payments 613 supporting records · 589 recipient NPIs · example record 1234298066 |
Xyrem · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1879 | 530 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 1736 | 404 |
| Prednisone | Prednisone | 932 | 323 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 607 | 168 |
| Alendronate Sodium | Alendronate Sodium | 467 | 119 |
| Breo Ellipta | Fluticasone/Vilanterol | 253 | 58 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 222 | 55 |
| Ventolin Hfa | Albuterol Sulfate | 221 | 79 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 208 | 62 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 203 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 179 | 53 |
| Symbicort | Budesonide/Formoterol Fumarate | 146 | 46 |
| Modafinil | Modafinil | 142 | 27 |
| Cephalexin | Cephalexin | 139 | 115 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 125 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 43 |
| Montelukast Sodium | Montelukast Sodium | 103 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 102 | 21 |
| Trazodone Hcl | Trazodone Hcl | 100 | 28 |
| Ofev | Nintedanib Esylate | 98 | 16 |
| Bumetanide | Bumetanide | 87 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 16 |
| Omeprazole | Omeprazole | 70 | 16 |
| Azithromycin | Azithromycin | 68 | 38 |
| Eliquis | Apixaban | 64 | 13 |
| Levofloxacin | Levofloxacin | 56 | 47 |
| Sildenafil Citrate | Sildenafil Citrate | 53 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 45 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 51 | 21 |
| Roflumilast | Roflumilast | 48 | suppressed |
| Armodafinil | Armodafinil | 47 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Famotidine | Famotidine | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 11 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Furosemide | Furosemide | 40 | 15 |
| Methylprednisolone | Methylprednisolone | 40 | 37 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Dupixent Pen | Dupilumab | 37 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 37 | 30 |
| Methylphenidate Hcl | Methylphenidate Hcl | 36 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 34 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 32 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 31 | 13 |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Gabapentin | Gabapentin | 27 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 24 |
| Dupixent Syringe | Dupilumab | 25 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Lisinopril | Lisinopril | 23 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Xolair | Omalizumab | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 14 | 12 |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Glassia | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 12 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Xyrem | Sodium Oxybate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Pirfenidone | Pirfenidone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72,592.21 · 226 records | AstraZeneca Pharmaceuticals LP | ACTHAR, AIRSENSE, AIRSUPRA, AREXVY, Arikayce, BEVESPI AEROSPHERE, BREZTRI, Brinsupri, CHARTIS CATHETER, DUPIXENT, ELIQUIS, FARXIGA, FASENRA, GLASSIA, JASCAYD, MOUNJARO, NUCALA, OFEV, Ohtuvayre, Ozempic, PROLIA, PULMONX CHARTIS TABLET CONSOLE, Prolastin-C Liquid, Rybelsus, SMARTVEST, Sunosi, TAVNEOS, TEZSPIRE, TRELEGY ELLIPTA, Tymlos, Tyvaso, Vest Therapy Und, WAKIX, WINREVAIR, Wegovy, XYWAV, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE, ZERBAXA, Zemaira | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error